Inventiva makes progress in its exclusive licensing agreement with Hepalys that was announced in September 2023 to develop and commercialize lanifibranor for the treatment of MASH patients in Japan and South Korea. The first participant has now been dosed in a Ph1 study to assess the safety, tolerability and PK/PD profile of the drug. Upon completion of this study and following Inventiva's EU/US pivotal NATiV3 readout, Inventiva and Hepalys could advance into a pivotal study for the region. We s...
Dsm firmenich has retrieved a solid earnings momentum in FY24, even without including the temporary benefit from higher vitamin prices on the back of a supply side disruption. Whilst the FY25 adjusted EBITDA growth guidance of at least 13% is still boosted by a combination of savings and synergies, we believe a mid single digit growth for the medium term is a realistic scenario. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcoming separation of the...
The acceleration of volume growth to 9% in 4Q24 is another testimony of the potential growth in North America. After recent divestment agreements on the Brazilian and Turkish businesses, Ontex will soon complete its strategic transformation and become a private-label focussed personal hygiene player in Europe and North America. Whilst Ontex is an established market leader in Europe, it is a challenger in North America which is characterized by much lower penetration of private label products. Wh...
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASHThe study represents the first significant step of Inventiva’s and Hepalys’s partnership toward the development of lanifibranor in Japan and South Korea Daix (France), New York City (New...
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1 Lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant à l'étude de Phase 1Des résultats positifs pourraient supporter le lancement d'une étude de Phase 3 pivot chez des patients atteints de MASH au JaponCette étude représente la première étape significative du partenariat entre Inventiva et Hepalys Pharma en vue du développement de lanifibranor au Ja...
Ontex has released its FY 2024 numbers. The company continued to deliver on its transformation plan, with credit stats improving further. Ontex guided for a constructive FY 2025. This should be driven by volumes, on the back of continuing positive momentum. We expect modest earnings improvement and disposals to support further improvement in the credit profile this year. We believe Ontex will refinance the HY bonds in the coming months.
Carrefour: full-year earnings and launch of strategic assets review|OPmobility: solid 2024 results and positive outlook in a challenging environment|Groupe Bruxelles Lambert (GBL) said to be mulling Imerys minority buyout (Bloomberg)|Verallia recovers slightly in Q4 and takes a cautious view of 2025|
Carrefour : résultats annuels et lancement d’une revue des actifs stratégiques|OPmobility : résultats 2024 solides et perspectives positives dans un environnement difficile|GBL étudierait un rachat des parts des minoritaires d’Imerys (Bloomberg)|Verallia se redresse légèrement au T4 et entrevoit 2025 avec prudence|
In today's Morning Views publication we comment on developments of the following high yield issuers: Nexans, TK Elevator, The Very Group, Liberty Global, Tereos, Ontex, Recordati, TI Fluid Systems, THOM Europe, Borr Drilling, Klockner Pentaplast, Casino Guichard-Perrachon
Below are the highlights from the conference call. We remind that like-for-like revenue growth picked up in 4Q24 on the back up of the ramp-up of new contracts in North America, resulting in a 3% better than expected adjusted EBITDA. Ontex guides for 4-7% adj EBITDA growth in 2025 with consensus roughly at the midpoint of the range and KBCS slightly above. After recent divestment agreements on the Brazilian and Turkish businesses, Ontex will soon complete its strategic transformation and become ...
Tereos : 9M 24/25 results in line with expectations|Nexans: a very strong FY 2024, and a good performance expected in FY 2025.|KKR clashes with Fibercop management over a difference in EBTDA forecasts (FT)|SES : Moody’s revises the outlook to Negative from Stable, SES says FY24 results are better than expected|
Tereos : Résultats 9M 24/25 conforme aux attentes|Nexans: a very strong FY 2024, and a good performance expected in FY 2025.|FiberCop : conflit entre KKR et le management concernant les prévisions d’EBITDA (FT)|SES : Moody’s révise la perspective de Stable à Négative, SES indique que les résultats 2024 devraient être meilleurs que prévu|
Aedifica: Good results, positive message about tenants growth. AGEAS: BNP Paribas increase stake >15% ASR: 2H results and SBB in line, capital strength building up. Belgian Telecoms: Peer Telenet 4Q24 results, guiding for low to mid single digit EBITDAal decline EVS: Exceptional FCF, 2025 EBIT consensus to go up >7% on +10-15% like for like sales growth YoY Gimv: In close cooperation with WorxInvest KPN: VodafoneZiggo 4Q24 still weak, declining EBITDA guidance on “strategic customer initiatives”...
Like-for-like revenue growth picked up in 4Q24 on the back up of the ramp-up of new contracts in North America, resulting in a 3% better than expected adjusted EBITDA. Ontex guides for 4-7% adj EBITDA growth in 2025 with consensus roughly at the midpoint of the range and KBCS slightly above. After recent divestment agreements on the Brazilian and Turkish businesses, Ontex will soon complete its strategic transformation and become a private-label focussed personal hygiene player in Europe and Nor...
dsm-firmenich issues €750 million long-term bond Press Release dsm-firmenich issues €750 million long-term bond Kaiseraugst (Switzerland), Maastricht (Netherlands), February 19, 2025 dsm-firmenich today announces the successful launch of a €750 million bond with an 11-year maturity due in 2036, at a coupon of 3.375%. The bond will be issued by DSM B.V. and will be guaranteed by DSM-Firmenich AG pursuant to the previously established . The proceeds of the new bond will be used for general corporate purposes, including the refinancing of existing indebtedness. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.